118 related articles for article (PubMed ID: 33453242)
1. Rational design and evaluation of GLP-1 derivative for treating hyperglycemia combined with overexercise-induced myocardial injury.
Wang Y; Xia Z; Xie H; Dong J
Life Sci; 2021 May; 272():119030. PubMed ID: 33453242
[TBL] [Abstract][Full Text] [Related]
2. S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors.
Huang P; Meng L; Tan J; Gu X; Huang M; Huang F; Ma R; Wang J
Life Sci; 2021 Apr; 270():119136. PubMed ID: 33508289
[TBL] [Abstract][Full Text] [Related]
3. Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound.
Ding WX; Wang HY; Peng LJ; Zhang F; Yuan S; Zhao LH
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12423-12436. PubMed ID: 33336763
[TBL] [Abstract][Full Text] [Related]
4. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
[TBL] [Abstract][Full Text] [Related]
5. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
[TBL] [Abstract][Full Text] [Related]
6. A novel thrombin-based triagonist with diabetes-protective and weight-lowering potential.
Zhang J; Zhang Z; Ma C; Zeng L; Zhang Y; Wang P; Xu L
Life Sci; 2020 Sep; 256():117853. PubMed ID: 32470452
[TBL] [Abstract][Full Text] [Related]
7. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y
Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205
[TBL] [Abstract][Full Text] [Related]
8. Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents.
Han J; Huang Y; Chen X; Zhou F; Fei Y; Fu J
Eur J Med Chem; 2018 Sep; 157():177-187. PubMed ID: 30096651
[TBL] [Abstract][Full Text] [Related]
9. Engineering an enhanced thrombin-based GLP-1 analog with long-lasting glucose-lowering and efficient weight reduction.
Pan H; Xie Y; Lu W; Chen Y; Lu Z; Zhen J; Wang W; Shang A
RSC Adv; 2019 Sep; 9(53):30707-30714. PubMed ID: 35529389
[TBL] [Abstract][Full Text] [Related]
10. Novel mono-PEGylated dimeric GLP-1 conjugate with enhanced receptor activation and prolonged anti-diabetes efficacies.
Li P; Zhang J; Jia Y; Zhang Y
Life Sci; 2020 Aug; 254():117752. PubMed ID: 32387412
[TBL] [Abstract][Full Text] [Related]
11. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
12. Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals.
Cui J; Shang A; Wang W; Chen W
Life Sci; 2020 Nov; 260():118339. PubMed ID: 32841660
[TBL] [Abstract][Full Text] [Related]
13. Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications.
Xu S; Wang F; Li H; Wang Y; Fang D
Bioengineered; 2022 Mar; 13(3):4621-4633. PubMed ID: 34696658
[TBL] [Abstract][Full Text] [Related]
14. Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice.
Ji WW; Yu DA; Fan M; You M; Lu Y; Li EB; Xie N; Yan SS
Acta Diabetol; 2017 Jul; 54(7):685-693. PubMed ID: 28424924
[TBL] [Abstract][Full Text] [Related]
15. Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents.
Han J; Fu J; Yang Q; Zhou F; Chen X; Li C; Yin J
Eur J Med Chem; 2020 Jul; 198():112389. PubMed ID: 32388115
[TBL] [Abstract][Full Text] [Related]
16. Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
Zhong X; Chen Z; Chen Q; Zhao W; Chen Z
Molecules; 2019 Feb; 24(4):. PubMed ID: 30795583
[TBL] [Abstract][Full Text] [Related]
17. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
Wu Y; Ji T; Lv J; Wang Z
Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
[TBL] [Abstract][Full Text] [Related]
18. Novel dual glucagon-like peptide-1/ glucose-dependent insulinotropic polypeptide receptor agonist attenuates diabetes and myocardial injury through inhibiting hyperglycemia, inflammation and oxidative stress in rodent animals.
Wang Y; Cai F; Li G; Tao Y
Bioengineered; 2022 Apr; 13(4):9184-9196. PubMed ID: 35383532
[TBL] [Abstract][Full Text] [Related]
19. Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity.
Han J; Huang X; Sun L; Li Z; Qian H; Huang W
Biochem Pharmacol; 2013 Jul; 86(2):297-308. PubMed ID: 23707756
[TBL] [Abstract][Full Text] [Related]
20. Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist.
Wang Q; Chen K; Liu R; Zhao F; Gupta S; Zhang N; Prud'homme GJ
PLoS One; 2010 Sep; 5(9):e12734. PubMed ID: 20856794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
